This grand round has already taken place.
This presentation will provide a historical perspective on the evolution of biomarker testing and some of the issue that lead to the development of the ASCO/CAP ER/PR and HER2 testing guidelines. We will look at the important element that need to be standardized including preanalytic, analytic and post analytic aspect of tests and how these can help insure accurate and reliable test results, with a review of data from the University of Rochester related to preanalytic variables. Finally, we will discuss the importance of improving diagnostic tissue sample quality for current and future molecular testing as part of precision medicine.
Dates and Times
Start: 9/12/2019 12:00 PM
End: 9/12/2019 1:00 PM
1) To briefly review the underlying biology of ER and HER2 in breast cancer and why these biomarker represent ideal therapeutic target in breast cancer treatment.
2) To review the importance of standardizing breast cancer biomarker testing and its importance in helping to insure the accuracy of these tests.
3) To review the role of preanalytic variable and how these can impact the integrity of pathology specimen and their suitability for molecular testing in breast cancer and other solid tumor.
Pathology level 9 BST-145
100 Nicolls Rd
BST-145 Level 9
Stony Brook, NY 11794
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.